BioNTech Faces Escalating Legal Battle and Strategic Pivot

BioNTech sues Moderna over mRNA patents, reports 2025 financials March 10, and accelerates its cancer therapy pipeline with 15 Phase 3 trials planned by 2026.

BioNTech SE is navigating a critical period marked by a significant patent lawsuit, upcoming financial disclosures, and a continued strategic shift toward oncology. The German biotechnology firm finds itself engaged on multiple fronts as it advances its cancer treatment pipeline while contesting intellectual property rights in the lucrative vaccine market.

Leadership and Financial Outlook

The company’s executive team expanded on March 1 with the appointment of Kylie Jimenez as Chief People Officer. Her mandate is to develop human resources strategy supporting BioNTech’s planned evolution into a multi-product oncology enterprise by 2030.

Investors await the full-year 2025 results, scheduled for release on March 10. The company has previously raised its revenue guidance for 2025 to a range of €2.6 to €2.8 billion. As of the end of December, BioNTech held cash and cash equivalents totaling €17.2 billion. Looking ahead to 2026, management anticipates slightly declining revenue from its Comirnaty COVID-19 vaccine, citing revised vaccination guidelines in the United States and a market transition from multi-year government contracts to private commercial channels.

For the third quarter of 2025, the company reported revenue of €1.52 billion alongside a net loss of €28.7 million. Significant oncology-related revenue is not expected until after 2026.

Intellectual Property Dispute Intensifies

A major development is the initiation of legal proceedings against rival Moderna. BioNTech alleges that Moderna’s mNEXSPIKE COVID-19 vaccine utilizes patented mRNA technology. The core of the accusation is that the vaccine employs a construct encoding only key segments of the viral spike protein, rather than the full version—a method BioNTech claims to have developed and patented.

The financial stakes are substantial. Court documents indicate Moderna generated approximately $1.17 billion in COVID-19 vaccine sales through the third quarter of 2025, with mNEXSPIKE projected to constitute about 55% of its COVID vaccine sales for the 2025/2026 season. BioNTech is seeking damages, contending that Moderna has engaged in willful and ongoing patent infringement. Moderna has stated it will vigorously defend itself against the claims.

Oncology Pipeline Accelerates

The strategic refocusing on cancer therapies is gaining momentum. BioNTech aims to have 15 Phase 3 clinical trials underway by the end of 2026, with seven late-stage readouts anticipated in the current year. The long-term plan envisions at least 17 additional late-stage readouts by 2030 and beyond. The development portfolio is concentrated on cancers of the lung, breast, gastrointestinal tract, and gynecological system.

Over the past two years, the company has more than doubled its Phase 2 and Phase 3 trials to over 25. Recent progress includes encouraging Phase 2 data for its candidate pumitamig in treating triple-negative breast cancer and the finalized acquisition of CureVac. A collaboration with Bristol Myers Squibb also provided an inflow of $1.5 billion.

Divergent Analyst Perspectives

Market experts hold contrasting views on the stock. In mid-January, Goldman Sachs upgraded its rating, expressing a constructive outlook on the company’s strategic execution. Conversely, Leerink Partners downgraded the shares to "Market Perform" in early February, with its analysts suggesting the previous share price recovery left limited room for further near-term gains.